Skip to content

Study · Randomized controlled trial · n = 15 · 2021

9 results

Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes.

Gibbons C, Blundell J, Tetens Hoff S, Dahl K, Bauer R, Baekdal T

Diabetes, obesity & metabolism27 Nov 2020Cited by 116 (Europe PMC)

PMID33184979 (opens in a new tab)PMCIDPMC7839771 (opens in a new tab)DOI10.1111/dom.14255 (opens in a new tab)PepBankPUB-33184979
Read at sourcePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, oral semaglutide increased satiety versus placebo after a fat-rich breakfast.

    In plain wordsIn adults with type 2 diabetes, oral semaglutide made people feel fuller after a fat-rich breakfast than placebo did.

    Peptide
    Semaglutide
    Outcome
    IncreaseSatiety after a fat-rich breakfast
    Study

    n = 15

    Comparator
    Placebo
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    3 mg, 7 mg then 14 mg once daily (4-week dose escalation) · oral · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    After a fat-rich breakfast, there were significant differences in favour of oral semaglutide versus placebo for measures of satiety, hunger and for overall appetite score
    2 context sentences
    Summary · context
    was associated with increased satiety and fullness after a fat-rich breakfast
    Summary · context
    In this randomized, double-blind, placebo-controlled, two-period cross-over trial, 15 subjects with T2D received 12 weeks of treatment with once-daily oral semaglutide (4-week dose escalation from 3 to 7 to 14 mg) followed by placebo, or vice versa.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, hunger measures differed significantly in favour of oral semaglutide versus placebo after a fat-rich breakfast.

    In plain wordsIn adults with type 2 diabetes, hunger ratings after a fat-rich breakfast were better with oral semaglutide than with placebo.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedHunger after a fat-rich breakfast
    Study

    n = 15

    Comparator
    Placebo
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    3 mg, 7 mg then 14 mg once daily (4-week dose escalation) · oral · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    After a fat-rich breakfast, there were significant differences in favour of oral semaglutide versus placebo for measures of satiety, hunger and for overall appetite score
    1 context sentence
    Summary · context
    In this randomized, double-blind, placebo-controlled, two-period cross-over trial, 15 subjects with T2D received 12 weeks of treatment with once-daily oral semaglutide (4-week dose escalation from 3 to 7 to 14 mg) followed by placebo, or vice versa.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, the overall appetite score differed significantly in favour of oral semaglutide versus placebo after a fat-rich breakfast.

    In plain wordsIn adults with type 2 diabetes, overall appetite ratings after a fat-rich breakfast were better with oral semaglutide than with placebo.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedOverall appetite score after a fat-rich breakfast
    Study

    n = 15

    Comparator
    Placebo
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    3 mg, 7 mg then 14 mg once daily (4-week dose escalation) · oral · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    After a fat-rich breakfast, there were significant differences in favour of oral semaglutide versus placebo for measures of satiety, hunger and for overall appetite score
    1 context sentence
    Summary · context
    In this randomized, double-blind, placebo-controlled, two-period cross-over trial, 15 subjects with T2D received 12 weeks of treatment with once-daily oral semaglutide (4-week dose escalation from 3 to 7 to 14 mg) followed by placebo, or vice versa.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, oral semaglutide and placebo did not differ significantly in appetite measures after a standard breakfast.

    In plain wordsIn adults with type 2 diabetes, appetite ratings after a standard breakfast did not differ between oral semaglutide and placebo.

    Peptide
    Semaglutide
    Outcome
    No significant changeSatiety, hunger and appetite after a standard breakfast
    Study

    n = 15

    Comparator
    Placebo
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    3 mg, 7 mg then 14 mg once daily (4-week dose escalation) · oral · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    with no significant differences following a standard breakfast.
    1 context sentence
    Summary · context
    In this randomized, double-blind, placebo-controlled, two-period cross-over trial, 15 subjects with T2D received 12 weeks of treatment with once-daily oral semaglutide (4-week dose escalation from 3 to 7 to 14 mg) followed by placebo, or vice versa.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, oral semaglutide gave fewer food cravings than placebo.

    In plain wordsIn adults with type 2 diabetes, oral semaglutide gave fewer food cravings than placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseFood cravings
    Study

    n = 15

    Comparator
    Placebo
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    3 mg, 7 mg then 14 mg once daily (4-week dose escalation) · oral · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    Fewer food cravings and better eating control were seen with oral semaglutide versus placebo
    1 context sentence
    Summary · context
    In this randomized, double-blind, placebo-controlled, two-period cross-over trial, 15 subjects with T2D received 12 weeks of treatment with once-daily oral semaglutide (4-week dose escalation from 3 to 7 to 14 mg) followed by placebo, or vice versa.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, oral semaglutide gave better eating control than placebo.

    In plain wordsIn adults with type 2 diabetes, oral semaglutide gave better control of eating than placebo.

    Peptide
    Semaglutide
    Outcome
    IncreaseControl of eating
    Study

    n = 15

    Comparator
    Placebo
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    3 mg, 7 mg then 14 mg once daily (4-week dose escalation) · oral · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    better eating control were seen with oral semaglutide versus placebo
    1 context sentence
    Summary · context
    In this randomized, double-blind, placebo-controlled, two-period cross-over trial, 15 subjects with T2D received 12 weeks of treatment with once-daily oral semaglutide (4-week dose escalation from 3 to 7 to 14 mg) followed by placebo, or vice versa.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, mean body weight decreased by 2.7 kg with oral semaglutide and 0.1 kg with placebo.

    In plain wordsIn adults with type 2 diabetes, body weight fell more with oral semaglutide than with placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight change
    Study

    n = 15

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3 mg, 7 mg then 14 mg once daily (4-week dose escalation) · oral · 12 weeksAs given in this study (human).

    Measurements

    Mean body weight change
    −2.7 kg
    oral semaglutide
    Mean body weight change
    −0.1 kg
    placebo

    Source sentences

    Summary
    Overall, mean body weight decreased by 2.7 kg with oral semaglutide and 0.1 kg with placebo, mostly attributable to body fat mass loss.
    1 context sentence
    Summary · context
    In this randomized, double-blind, placebo-controlled, two-period cross-over trial, 15 subjects with T2D received 12 weeks of treatment with once-daily oral semaglutide (4-week dose escalation from 3 to 7 to 14 mg) followed by placebo, or vice versa.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, the weight loss with oral semaglutide was mostly body fat mass loss.

    In plain wordsIn adults with type 2 diabetes, most of the weight lost with oral semaglutide was body fat.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody fat mass
    Study

    n = 15

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3 mg, 7 mg then 14 mg once daily (4-week dose escalation) · oral · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    mostly attributable to body fat mass loss.
    2 context sentences
    Summary · context
    After 12 weeks of treatment, ad libitum energy intake was lower with oral semaglutide versus placebo, resulting in reduced body fat mass, and was associated with increased satiety and fullness after a fat-rich breakfast, and improved eating control.
    Summary · context
    In this randomized, double-blind, placebo-controlled, two-period cross-over trial, 15 subjects with T2D received 12 weeks of treatment with once-daily oral semaglutide (4-week dose escalation from 3 to 7 to 14 mg) followed by placebo, or vice versa.
  9. 09HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, oral semaglutide lowered total daily ad libitum energy intake by 38.9% versus placebo after a standard breakfast.

    In plain wordsIn adults with type 2 diabetes, oral semaglutide lowered how much people ate in a day compared with placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseTotal daily ad libitum energy intake after a standard breakfast
    Study

    n = 13

    Comparator
    Placebo
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    3 mg, 7 mg then 14 mg once daily (4-week dose escalation) · oral · 12 weeksAs given in this study (human).

    Measurements

    Energy intake difference
    38.9%
    oral semaglutide vs placebo
    Estimated treatment difference
    −5096 kJ
    oral semaglutide vs placebo

    Source sentences

    Summary
    Following a standard breakfast, total daily ad libitum energy intake was significantly lower (38.9%) with oral semaglutide versus placebo in 13 evaluable subjects (estimated treatment difference, -5096.0 kJ; 95% CI -7000.0, -3192.1; P = .0001).
    1 context sentence
    Summary · context
    In this randomized, double-blind, placebo-controlled, two-period cross-over trial, 15 subjects with T2D received 12 weeks of treatment with once-daily oral semaglutide (4-week dose escalation from 3 to 7 to 14 mg) followed by placebo, or vice versa.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 1NCT02773381

A Trial Investigating the Effect of Oral Semaglutide Compared With Placebo on Postprandial Glucose and Triglyceride Metabolism, Energy Intake, Appetite Sensations and Gastric Emptying in Subjects With Type 2 Diabetes

Novo Nordisk A/Sn = 152 Jun 2016 to 19 Oct 2018

Diabetes · Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 8 Dec 2020

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.